Market news

Pulmonx (NASDAQ:LUNG) shares fell 10. 1% to $2.

REDWOOD CITY, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that on September 1, 2026 (the “Grant Date”), Pulmonx granted equity awards under its 2025 Inducement Plan (the “Inducement Plan”) to four individuals hired by Pulmonx in the third fiscal quarter of 2026. The awards were approved by the Compensation Committee of the Company’s Board of Directors

REDWOOD CITY, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced that management will participate in the following upcoming investor conferences: Wells Fargo Healthcare ConferenceFormat: 1x1 meetingsDate: Wednesday, September 9Location: Boston, MA Lake Street Best Ideas Growth (BIG10) ConferenceFormat: 1x1 meetingsDate: Thursday, September 10Location: New York, NY About

Is it a good or bad thing when a stock experiences a golden cross technical event?

Does Pulmonx Corporation (LUNG) have what it takes to be a top stock pick for momentum investors? Let's find out.

Detailed price information for Pulmonx Corp (LUNG-Q) from The Globe and Mail including charting and trades.

Detailed price information for Pulmonx Corp (LUNG-Q) from The Globe and Mail including charting and trades.

Motley Fool Press Release.

Pulmonx (LUNG) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Moby summary of Pulmonx Corporation's Q2 2026 earnings call

REDWOOD CITY, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter of 2026 ended June 30, 2026. Recent Highlights Achieved worldwide revenue of $22.8 million in the second quarter of 2026, a 5% decrease over the same period last year and a decrease of 6% on a constant currency basisDelivered $14.2 million in U.S. revenue

Pulmonx (LUNG) delivered earnings and revenue surprises of +14.29% and +2.34%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Pulmonx (NASDAQ:LUNG) reported second-quarter revenue of $22.8 million and reiterated its full-year 2026 revenue outlook, while executives highlighted progress in rebuilding the U.S. sales organization, reducing operating expenses and preparing to resume shipments to China. Revenue for the quarter

REDWOOD CITY, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference in Boston on Tuesday, August 11, 2026, at 1:00 PM PT / 4:00 PM ET. A live and archived webcast of the fireside chat will be available on “Investors” section of the Pulmonx website at https://investor

REDWOOD CITY, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2026 after the close of trading on Wednesday, July 29, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET. A live and archived webcast of the event will be available on the “In